J Cancer 2017; 8(11):2079-2087. doi:10.7150/jca.19181 This issue Cite

Research Paper

A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma

Xue-Ping Wang1†, Min- Jie Mao1†, Zhong-Lian He2, Lin Zhang1,3, Pei-Dong Chi1, Jia-rui Su4, Shu-Qin Dai1✉, Wan-Li Liu1✉

1. Department of Laboratory Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China
2. Department of Information section, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China
3. Guangdong Esophageal Cancer Institute
4. Guangdong Medical University, 523808, China.
Equal contributors

Citation:
Wang XP, Mao MJ, He ZL, Zhang L, Chi PD, Su Jr, Dai SQ, Liu WL. A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma. J Cancer 2017; 8(11):2079-2087. doi:10.7150/jca.19181. https://www.jcancer.org/v08p2079.htm
Other styles

File import instruction

Abstract

Aims: The levels of coagulation system tests have been studied in various cancers. In this study, our aim is to evaluate the prognostic value of pretreatment plasma coagulation tests in hepatocellular carcinoma (HCC) patients.

Patient and methods: A retrospective study was performed in 539 patients with HCC, and follow-up period was at least 60 months until recurrence or death. The prognostic significance of coagulation system tests (prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen) were determined by univariate and multivariate Cox hazard models. Then, according to the results of the multivariate analyses, we proposed the coagulation-Based Stage, which combined the independent risk factors (prothrombin time and fibrinogen).

Results: Coagulation system tests including prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (Fbg) were analyzed. Patients with prolonged PT (≥12.1 sec) levels had significantly poor overall survival (OS) and disease-free survival (DFS), not only in the entire cohort (HR: 1.661, 95%CI: 1.125-2.451, p=0.011 vs. HR: 1.660, 95%CI: 1.125-2.451, p=0.011), but also in the subgroups stratified by pathological stage (stage I-II and stage III-IV). Additionally, high Fbg (≥2.83 g/L) levels experienced significantly decreased OS and DFS (HR: 2.158, 95%CI: 1.427-3.263, p<0.001 vs. HR: 2.161, 95%CI: 1.429-3.267, p<0.001), not only in the entire cohort but also in the subgroups stratified by pathological stage (stage I-II and stage III-IV). All the patients were then stratified (based on combined PT and Fbg) into three groups, The OS for HCC patients were (41.37±17.76), (31.83±19.84) and (18.68±18.41) months, and the DFS for HCC patients were (41.15±17.88), (31.65±19.81) and (18.66±18.39) months.

Conclusions: Our findings suggest that the combination of plasma PT and Fbg levels should be evaluated as the valuable predictor of survival in patients with HCC.

Keywords: HCC, prothrombin time, fibrinogen, prognosis, overall survival, disease-free survival


Citation styles

APA
Wang, X.P., Mao, M.J., He, Z.L., Zhang, L., Chi, P.D., Su, J.r., Dai, S.Q., Liu, W.L. (2017). A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma. Journal of Cancer, 8(11), 2079-2087. https://doi.org/10.7150/jca.19181.

ACS
Wang, X.P.; Mao, M.J.; He, Z.L.; Zhang, L.; Chi, P.D.; Su, J.r.; Dai, S.Q.; Liu, W.L. A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma. J. Cancer 2017, 8 (11), 2079-2087. DOI: 10.7150/jca.19181.

NLM
Wang XP, Mao MJ, He ZL, Zhang L, Chi PD, Su Jr, Dai SQ, Liu WL. A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma. J Cancer 2017; 8(11):2079-2087. doi:10.7150/jca.19181. https://www.jcancer.org/v08p2079.htm

CSE
Wang XP, Mao MJ, He ZL, Zhang L, Chi PD, Su Jr, Dai SQ, Liu WL. 2017. A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma. J Cancer. 8(11):2079-2087.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image